<DOC>
	<DOCNO>NCT01690403</DOCNO>
	<brief_summary>Primary Objective : - To evaluate effect single repeat administration rifapentine give daily weekly regimen steady-state pharmacokinetic parameter efavirenz , emtricitabine tenofovir give fix dose combination ( ATRIPLA™ ) . Secondary Objective : - To evaluate safety tolerability concomitant administration rifapentine ATRIPLA™ give HIV+ patient</brief_summary>
	<brief_title>Interaction Study Assess Pharmacokinetic Interaction Oral Administration Rifapentine ATRIPLA™ HIV Patients</brief_title>
	<detailed_description>- Screening admission : 21 day - Admission end follow-up : 41 day - Period 1 : Treatment period 15 day ATRIPLA™ ( background therapy ) . Patients receive regimen dose ATRIPLA™ study screen period 1 . - Period 2 : Treatment period 21 day co-administration rifapentine . - Follow : 3 5 day last rifapentine administration .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Inclusion criterion : HIV+ male female patient receive ATRIPLA™ age 18 55 year old CD4 count cell least 350 Exclusion criterion : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , haematological ( patient porphyria ) , neurological , osteomuscular , articular , psychiatric , systemic , ocular , gynaecologic ( female ) , infectious disease , sign acute illness HIV disease . Active latent tuberculosis infection The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>